Litigation
In re Thalomid and Revlimid Antitrust Litigation
active2:14-cv-06997
Auto-generating section 1 of 5: Case overview & background…
Each section takes ~30-60s with web-search grounding. Keep this tab open — sections will fill in below as they complete.
Patents at issue (1)
Defendants (2)
Summary
Antitrust litigation by purchaser/insurer classes against Celgene/BMS, in which the '106 patent is directly referenced as part of Celgene's Revlimid patent portfolio/alleged monopolization scheme. The case remains ongoing with appeals and summary-judgment briefing in 2024 (see Dkt. 446, 2:19-cv-07532).
Case overview & background
Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Key legal developments & outcome
Major rulings, motions, claim construction, settlements, and the present posture or final disposition.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
In the news
What the press has reported about this case, summarized with links to the source articles.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Plaintiff representatives
Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Defendant representatives
Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).